Hoffman: FTC won't accept pipeline divestitures in certain mergers

The acting director of the Federal Trade Commission's bureau of competition has said that the commission will no longer accept the divestiture of pipeline products to remedy anticompetitive mergers in the inhalant and injectable drug industries.

Get unlimited access to all Global Competition Review content